Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 7.773
Filter
1.
Ghana Med J ; 58(1): 86-90, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38957275

ABSTRACT

Objective: This study aims to examine the frequency of Salmonella Paratyphi found in blood cultures and evaluate the antibiotic susceptibility pattern of Salmonella isolates to different antibiotics. Additionally, the study aims to assess the paradigm shift in the trend of enteric fever caused by Salmonella Typhi (S. Typhi) to Salmonella Paratyphi(S. Paratyphi) . Study Design: Retrospective study. Participant: The study enrolled patients aged 12 years and above diagnosed with enteric fever (positive blood culture) and admitted to Peelamedu Samanaidu Govindasamy Naidu (PSG) Hospital. Interventions: The study analyzed demographic and antibiotic susceptibility profiles of Salmonella isolates collected from 106 enteric fever patients in the hospital between 2010 and 2022. The susceptibility profiles of Salmonella isolates to multiple antibiotics were assessed. Results: There were 106 participants, and 95 (89.62%) of them had enteric fever linked to Salmonella Typhi, while only 11 (10.38%) had enteric fever linked to Salmonella Paratyphi A. From 2010 to 2022, the study discovered a general decline in the prevalence of enteric fever caused by Salmonella species. But between 2014 and 2022, the incidence of enteric fever linked to S. Typhi rapidly increased. Azithromycin (100% , n = 106) and ceftriaxone (99% , n = 105) were highly effective against the Salmonella isolates, whereas nalidixic acid was resisted by 3 isolates (4.72%, n = 3). Conclusion: The study observed a higher incidence of Salmonella Typhi in comparison to Paratyphi A and a greater susceptibility of males to enteric fever. Funding: None declared.


Subject(s)
Anti-Bacterial Agents , Microbial Sensitivity Tests , Salmonella paratyphi A , Salmonella typhi , Typhoid Fever , Humans , Male , Female , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Typhoid Fever/epidemiology , Typhoid Fever/microbiology , Typhoid Fever/drug therapy , Retrospective Studies , Salmonella typhi/drug effects , Salmonella typhi/isolation & purification , Salmonella paratyphi A/drug effects , Salmonella paratyphi A/isolation & purification , Adult , Adolescent , Child , Middle Aged , Young Adult , Paratyphoid Fever/epidemiology , Paratyphoid Fever/microbiology , Paratyphoid Fever/drug therapy , Incidence , Drug Resistance, Bacterial , Azithromycin/therapeutic use , Azithromycin/pharmacology , Ceftriaxone/therapeutic use , Ceftriaxone/pharmacology , Aged , Prevalence
2.
Aust J Gen Pract ; 53(7): 499-503, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38959520

ABSTRACT

BACKGROUND AND OBJECTIVES: There were 82.4 million new gonorrhoea cases worldwide in 2020. Dual treatment with ceftriaxone or cefixime and azithromycin or doxycycline is currently recommended for gonorrhoea in Indonesia. However, reduced susceptibility and resistance to cephalosporins and azithromycin are increasing. We evaluated the susceptibility pattern of Neisseria gonorrhoeae to cefixime, ceftriaxone, azithromycin and doxycycline. METHOD: N. gonorrhoeae isolates were obtained from 19 male participants with clinically and laboratory-confirmed gonorrhoea. Antibiotic susceptibility testing was conducted by disc diffusion and interpreted according to Clinical and Laboratory Standards Institute and Centers for Disease Control and Prevention criteria. RESULTS: Reduced susceptibility or resistance was observed against doxycycline in 19 isolates (100%), cefixime in six (31.6%), ceftriaxone in three (15.8%) and azithromycin in zero (0%) isolates. DISCUSSION: A dual treatment regimen with ceftriaxone and azithromycin can still be recommended as first-line therapy for gonorrhoea in Indonesia. Antibiotic susceptibility surveillance of N. gonorrhoeae should be routinely conducted.


Subject(s)
Anti-Bacterial Agents , Azithromycin , Ceftriaxone , Doxycycline , Gonorrhea , Microbial Sensitivity Tests , Neisseria gonorrhoeae , Humans , Indonesia , Neisseria gonorrhoeae/drug effects , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Gonorrhea/drug therapy , Male , Microbial Sensitivity Tests/methods , Azithromycin/therapeutic use , Doxycycline/therapeutic use , Ceftriaxone/therapeutic use , Ceftriaxone/pharmacology , Adult , Cefixime/therapeutic use , Cefixime/pharmacology , Primary Health Care/statistics & numerical data , Drug Resistance, Bacterial/drug effects , Drug Therapy, Combination/methods
3.
Georgian Med News ; (349): 98-102, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38963211

ABSTRACT

We report a severe case of a 25-year-old girl presented with complaints of weakness, diarrhoea, vomiting, pain in abdomen and hypotension at Infectious Diseases and Clinical Immunology Research Center. From history on 25 February till 29 February she was in India and on 1 march this problem started with watery diarrhoea followed by vomiting. She ate pizza with mushroom following which her condition worsened. Stool culture revealed salmonella nontyphi (nonthyphodal Salmonella)and this is leading cause for gastroenteritis, bacteremia and affects several other bodily system. Her condition deteriorated due to the development of ARDS (acute respiratory distress syndrome) and for this she was on mechanical ventilation. Vitec machine was performed, which identified Salmonella typhi murium. Our goal is to manage and treat this patient well by early diagnosis. She was given ceftriaxone, iv fluids and symptomatic treatment but due to resistance meropenem was started and the patient's condition improved. From serology there was no evidence of immunocompromised state so being a severe case of immunocompetent patient this case reflects the importance of timely diagnosis and management together with food safety practices in population. On follow up she was stable and discharged after 3 weeks. Future research studies need to be continued regarding newer strains, effective treatment strategies and diagnostics to prevent morbidity and mortality.


Subject(s)
Salmonella Infections , Adult , Female , Humans , Anti-Bacterial Agents/therapeutic use , Ceftriaxone/therapeutic use , Diarrhea/microbiology , Meropenem/therapeutic use , Multiple Organ Failure/microbiology , Multiple Organ Failure/etiology , Respiratory Distress Syndrome/microbiology , Respiratory Distress Syndrome/etiology , Salmonella Infections/diagnosis , Salmonella Infections/drug therapy , Salmonella Infections/microbiology , Salmonella Infections/complications , Salmonella typhimurium/isolation & purification
4.
Pan Afr Med J ; 47: 156, 2024.
Article in French | MEDLINE | ID: mdl-38974695

ABSTRACT

Lyme neuroborreliosis is a rare zoonosis which can be difficult to diagnose, in particular in low endemic areas. We here report the case of a 35-year-old man presenting with disabling back pain preceded by facial monoplegia, which was wrongly treated as Bell's palsy (paralysis a frigore) and then as post-traumatic lumbosciatica. The onset of facial diplegia allowed for a definitive diagnosis. The patient was treated with ceftriaxone and symptoms gradually improved.


Subject(s)
Anti-Bacterial Agents , Bell Palsy , Ceftriaxone , Facial Paralysis , Lyme Neuroborreliosis , Humans , Male , Adult , Facial Paralysis/etiology , Facial Paralysis/diagnosis , Anti-Bacterial Agents/administration & dosage , Ceftriaxone/administration & dosage , Lyme Neuroborreliosis/diagnosis , Lyme Neuroborreliosis/complications , Lyme Neuroborreliosis/drug therapy , Bell Palsy/diagnosis , Bell Palsy/etiology , Back Pain/etiology , Diagnostic Errors , Lyme Disease/diagnosis , Lyme Disease/complications , Lyme Disease/drug therapy , Low Back Pain/etiology
5.
Emerg Infect Dis ; 30(8): 1683-1686, 2024 Aug.
Article in English | MEDLINE | ID: mdl-39043453

ABSTRACT

Ceftriaxone-resistant Neisseria gonorrhoeae FC428-like strains have disseminated across the Asia-Pacific region, with a continuous rise in prevalence during 2015-2022. To mitigate the effect of these strains, we advocate for enhanced molecular diagnostics, expanded surveillance networks, and a regionally coordinated effort to combat the global spread of FC428-like strains.


Subject(s)
Anti-Bacterial Agents , Ceftriaxone , Drug Resistance, Bacterial , Gonorrhea , Neisseria gonorrhoeae , Neisseria gonorrhoeae/drug effects , Neisseria gonorrhoeae/genetics , Ceftriaxone/pharmacology , Humans , Gonorrhea/microbiology , Gonorrhea/epidemiology , Gonorrhea/drug therapy , Asia/epidemiology , Anti-Bacterial Agents/pharmacology , Microbial Sensitivity Tests , Prevalence , History, 21st Century
6.
Sex Health ; 212024 Jul.
Article in English | MEDLINE | ID: mdl-39008622

ABSTRACT

Background Gonorrhoea notifications have increased substantially in Australia over the past decade. Neisseria gonorrhoeae is already highly resistant to several antibiotics and so, alternatives to first-line treatment are generally strongly discouraged. The penicillin allergy label (AL) on patient medical records has previously been shown to influence prescribing practices, to the detriment of best-practice management and antimicrobial stewardship. This study aimed to understand how the penicillin AL influences antibiotic selection for gonorrhoea treatment at Canberra Sexual Health Centre. Methods A retrospective chart audit of gonorrhoea cases treated at Canberra Sexual Health Centre between January 2020 and October 2023 (n =619 patients, n =728 cases). Antibiotic selection was assessed according to penicillin AL status. Ceftriaxone selection was assessed according to penicillin allergy severity reported in the medical records and as determined using a validated antibiotic allergy assessment tool. Results Cases with a penicillin AL were more likely to receive antibiotics other than ceftriaxone (n =7/41, 17.1%) than cases without the label (n =8/687, 1.2%, P n =28/41, 68.3%) to apply the assessment tool. Those reported as low-severity in the records were more likely to receive ceftriaxone (n =21/22, 95.5%) than those reported as moderate-high (n =7/11, 63.6%) or unreported (n =6/8, 0.75%). Conclusions Treatment of gonorrhoea in outpatient settings requires an understanding of penicillin allergy, and the ability to quickly and accurately identify penicillin-AL patients who can safely tolerate ceftriaxone. Institutionally endorsed penicillin allergy de-labelling protocols and access to easy-to-navigate prescribing advice within national sexually transmitted infection management guidelines would support this.


Subject(s)
Anti-Bacterial Agents , Ceftriaxone , Drug Hypersensitivity , Gonorrhea , Penicillins , Humans , Gonorrhea/drug therapy , Ceftriaxone/therapeutic use , Retrospective Studies , Anti-Bacterial Agents/therapeutic use , Penicillins/therapeutic use , Penicillins/adverse effects , Female , Male , Adult , Neisseria gonorrhoeae , Australia , Medical Records , Practice Patterns, Physicians'/statistics & numerical data , Middle Aged , Drug Labeling
7.
J Investig Med High Impact Case Rep ; 12: 23247096241261508, 2024.
Article in English | MEDLINE | ID: mdl-38877708

ABSTRACT

Nocardia pyomyositis in immunocompetent patients is a rare occurrence. The diagnosis may be missed or delayed with the risk of progressive infection and suboptimal or inappropriate treatment. We present the case of a 48-year-old immunocompetent firefighter diagnosed with pyomyositis caused by Nocardia brasiliensis acquired by direct skin inoculation from gardening activity. The patient developed a painful swelling on his right forearm that rapidly progressed proximally and deeper into the underlying muscle layer. Ultrasound imaging of his right forearm showed a 7-mm subcutaneous fluid collection with surrounding edema. Microbiologic analysis of the draining pus was confirmed to be N brasiliensis by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) Mass Spectrometry. After incision and drainage deep to the muscle layer to evacuate the abscess and a few ineffective antibiotic options, the patient was treated with intravenous ceftriaxone and oral linezolid for 6 weeks. He was then de-escalated to oral moxifloxacin for an additional 4 months to complete a total antibiotic treatment duration of 6 months. The wound healed satisfactorily and was completely closed by the fourth month of antibiotic therapy. Six months after discontinuation of antibiotics, the patient continued to do well with complete resolution of the infection. In this article, we discussed the risk factors for Nocardia in immunocompetent settings, the occupational risks for Nocardia in our index patient, and the challenges encountered with diagnosis and treatment. Nocardia should be included in the differential diagnosis of cutaneous infections, particularly if there is no improvement of "cellulitis" with traditional antimicrobial regimens and the infection extends into the deeper muscle tissues.


Subject(s)
Anti-Bacterial Agents , Gardening , Immunocompetence , Nocardia Infections , Nocardia , Pyomyositis , Humans , Male , Middle Aged , Nocardia Infections/diagnosis , Nocardia Infections/drug therapy , Nocardia/isolation & purification , Anti-Bacterial Agents/therapeutic use , Pyomyositis/drug therapy , Pyomyositis/diagnosis , Pyomyositis/microbiology , Ceftriaxone/therapeutic use , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Drainage , Moxifloxacin/therapeutic use , Moxifloxacin/administration & dosage , Linezolid/therapeutic use
8.
P R Health Sci J ; 43(2): 68-72, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38860959

ABSTRACT

OBJECTIVE: Monitoring the susceptibility patterns of Neisseria gonorrhoeae is essential for the continuing compliance with current treatment recommendations. Puerto Rico conducts susceptibility tests on N. gonorrhoeae; however, trends on antimicrobial resistance in the island have not been reported since the mid 80's. METHODS: We performed a secondary analysis of a national data repository on the antimicrobial susceptibility of N. gonorrhoeae isolates between 2012 and 2017; a period of time when the CDC recommended a single dose of ceftriaxone and azithromycin for the treatment of uncomplicated gonorrhea. Data on susceptibility to eight antibiotics using the standard disk diffusion method was obtained for 30.0% (84/276) of the samples collected from the Sexually Transmitted Disease clinics in Puerto Rico. We also performed patient demographic analyses linked to resistance. RESULTS: Rates of resistance to ceftriaxone and azithromycin were 0% and 4.0% (2/50), respectively. The percentage of isolates resistant to antimicrobials no longer recommended in Puerto Rico, such as tetracycline, ciprofloxacin, and penicillin, was 86.0% (43/50), 76.0% (38/50), and 38.0% (19/50), respectively. Prevalence of resistant N. gonorrhoeae was higher among men who have sex with men, MSM (79%, 37/47). DISCUSSION: Lack of resistance to ceftriaxone and slow emergence of azithromycin resistance was identified from 2012-2017. It is imperative to continue the surveillance for emerging patterns of resistance, especially for ceftriaxone, as it is part of the current treatment guidelines. Therefore, protocols for culture based surveillance, including sample transport and processing, should be strengthened to ensure quality assured epidemiology of gonococcal resistance in Puerto Rico.


Subject(s)
Anti-Bacterial Agents , Drug Resistance, Bacterial , Gonorrhea , Microbial Sensitivity Tests , Neisseria gonorrhoeae , Puerto Rico , Neisseria gonorrhoeae/drug effects , Neisseria gonorrhoeae/isolation & purification , Humans , Male , Gonorrhea/drug therapy , Gonorrhea/microbiology , Gonorrhea/epidemiology , Female , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/administration & dosage , Adult , Young Adult , Azithromycin/pharmacology , Azithromycin/administration & dosage , Ceftriaxone/pharmacology , Adolescent , Middle Aged
9.
J Infect ; 89(2): 106202, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38897240

ABSTRACT

OBJECTIVES: To determine whether concomitant use of ceftriaxone and oral or intravenous lansoprazole increases the risk of ventricular arrhythmia and cardiac arrest in the real-world setting in Japan. METHODS: The data analyzed were obtained from the JMDC hospital-based administrative claims database for the period April 2014 to August 2022. Patients who received a proton pump inhibitor (PPI) while receiving ceftriaxone or sulbactam/ampicillin were identified. The frequency of ventricular arrhythmia and cardiac arrest was analyzed according to whether oral or intravenous PPI was concomitant with ceftriaxone or sulbactam/ampicillin. Estimates of the incidence of ventricular arrhythmia and cardiac arrest were then compared among the groups, using the Fine-Gray competing risk regression model. RESULTS: The results showed that the risk of ventricular arrhythmia and cardiac arrest was significantly higher with concomitant ceftriaxone and oral lansoprazole (hazard ratio 2.92, 95% confidence interval 1.99-4.29, P < 0.01) or intravenous lansoprazole (hazard ratio 4.57, 95% confidence interval 1.24-16.80, P = 0.02) than with concomitant sulbactam/ampicillin and oral or intravenous lansoprazole. CONCLUSIONS: Oral and intravenous lansoprazole may increase the risk of ventricular arrhythmia and cardiac arrest in patients who are receiving ceftriaxone.


Subject(s)
Arrhythmias, Cardiac , Ceftriaxone , Heart Arrest , Lansoprazole , Proton Pump Inhibitors , Humans , Lansoprazole/adverse effects , Lansoprazole/administration & dosage , Ceftriaxone/adverse effects , Ceftriaxone/administration & dosage , Heart Arrest/chemically induced , Heart Arrest/epidemiology , Male , Japan/epidemiology , Female , Aged , Middle Aged , Proton Pump Inhibitors/adverse effects , Proton Pump Inhibitors/administration & dosage , Arrhythmias, Cardiac/chemically induced , Arrhythmias, Cardiac/epidemiology , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/administration & dosage , Databases, Factual , Aged, 80 and over , Adult , Retrospective Studies , Incidence , Administration, Oral , Risk Factors , Drug Therapy, Combination/adverse effects , East Asian People
10.
Microbiome ; 12(1): 80, 2024 May 07.
Article in English | MEDLINE | ID: mdl-38715137

ABSTRACT

BACKGROUND: Antibiotic exposure can occur in medical settings and from environmental sources. Long-term effects of brief antibiotic exposure in early life are largely unknown. RESULTS: Post a short-term treatment by ceftriaxone to C57BL/6 mice in early life, a 14-month observation was performed using 16S rRNA gene-sequencing technique, metabolomics analysis, and metagenomics analysis on the effects of ceftriaxone exposure. Firstly, the results showed that antibiotic pre-treatment significantly disturbed gut microbial α and ß diversities (P < 0.05). Both Chao1 indices and Shannon indices manifested recovery trends over time, but they didn't entirely recover to the baseline of control throughout the experiment. Secondly, antibiotic pre-treatment reduced the complexity of gut molecular ecological networks (MENs). Various network parameters were affected and manifested recovery trends over time with different degrees, such as nodes (P < 0.001, R2 = 0.6563), links (P < 0.01, R2 = 0.4543), number of modules (P = 0.0672, R2 = 0.2523), relative modularity (P = 0.6714, R2 = 0.0155), number of keystones (P = 0.1003, R2 = 0.2090), robustness_random (P = 0.79, R2 = 0.0063), and vulnerability (P = 0.0528, R2 = 0.28). The network parameters didn't entirely recover. Antibiotic exposure obviously reduced the number of key species in gut MENs. Interestingly, new keystones appeared during the recovery process of network complexity. Changes in network stability might be caused by variations in network complexity, which supports the ecological theory that complexity begets stability. Besides, the metabolism profiles of the antibiotic group and control were significantly different. Correlation analysis showed that antibiotic-induced differences in gut microbial metabolism were related to MEN changes. Antibiotic exposure also caused long-term effects on gut microbial functional networks in mice. CONCLUSIONS: These results suggest that short-term antibiotic exposure in early life will cause long-term negative impacts on gut microbial diversity, MENs, and microbial metabolism. Therefore, great concern should be raised about children's brief exposure to antibiotics if the results observed in mice are applicable to humans. Video Abstract.


Subject(s)
Anti-Bacterial Agents , Bacteria , Gastrointestinal Microbiome , Mice, Inbred C57BL , RNA, Ribosomal, 16S , Gastrointestinal Microbiome/drug effects , Animals , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/adverse effects , Mice , RNA, Ribosomal, 16S/genetics , Bacteria/genetics , Bacteria/classification , Bacteria/metabolism , Bacteria/drug effects , Ceftriaxone/pharmacology , Metagenomics/methods , Male , Metabolomics , Feces/microbiology
11.
J Antimicrob Chemother ; 79(7): 1619-1627, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38804149

ABSTRACT

OBJECTIVES: The quality of amoxicillin capsules, ceftriaxone for injection, and ciprofloxacin tablets was evaluated to determine whether there is any difference in quality when comparing the country of origin. This was undertaken because it has been claimed that antibiotics manufactured in Europe are of superior quality to those originating from Africa or Asia. METHODS: Samples of amoxicillin capsules, ceftriaxone for injection, and ciprofloxacin tablets were collected from three randomly selected wholesale pharmacies in each city, namely Arusha, Dar es Salaam and Mwanza, Tanzania. The collected samples of collected brands were subjected to quality control testing as per their respective pharmacopoeial monographs. Amoxil 250 mg capsules (Glaxo Wellcome, Mayenne, France), Rocephin (Roche, Switzerland) and Cipro-Denk 500 (Allphamed Pharbil Arzneimittel GmbH, Gottingen, Germany) were used as reference brands for the other generic brands of amoxicillin, ceftriaxone and ciprofloxacin, respectively. RESULTS: A total of 31 brands (10 different brands of amoxicillin capsules, 9 of ceftriaxone sodium injections, and 12 of ciprofloxacin tablets) were collected from the targeted regions and subjected to quality control testing. All samples of collected brands complied with the requirements of their respective pharmacopoeial monographs. CONCLUSIONS: There was no significant difference in quality between brands of amoxicillin capsules, ceftriaxone for injection, and ciprofloxacin tablets manufactured in Africa and Asia against those manufactured in Europe in terms of compliance with the respective pharmacopoeial monographs.


Subject(s)
Anti-Bacterial Agents , Ciprofloxacin , Quality Control , Tanzania , Anti-Bacterial Agents/analysis , Ciprofloxacin/analysis , Humans , Ceftriaxone/analysis , Ceftriaxone/chemistry , Amoxicillin/analysis , Amoxicillin/standards , Amoxicillin/chemistry , Tablets
12.
Sex Transm Infect ; 100(4): 226-230, 2024 May 31.
Article in English | MEDLINE | ID: mdl-38702191

ABSTRACT

OBJECTIVES: Antibiotic resistance in gonorrhoea is of significant public health concern with the emergence of resistance to last-line therapies such as ceftriaxone. Despite around half of Neisseria gonorrhoeae isolates tested in the UK being susceptible to ciprofloxacin, very little ciprofloxacin is used in clinical practice. Testing for the S91F mutation associated with ciprofloxacin resistance is now available in CE-marked assays and may reduce the requirement for ceftriaxone, but many patients are treated empirically, or as sexual contacts, which may limit any benefit. We describe the real-world impact of such testing on antimicrobial use and clinical outcomes in people found to have gonorrhoea in a large urban UK sexual health clinic. METHODS: Molecular ciprofloxacin resistance testing (ResistancePlus GC assay (SpeeDx)) was undertaken as an additional test after initial diagnosis (m2000 Realtime CT/NG assay (Abbott Molecular)) in those not already known to have had antimicrobial treatment. Data from a 6-month period (from March to September 2022) were analysed to determine treatment choice and treatment outcome. RESULTS: A total of 998 clinical samples tested positive for N. gonorrhoeae in 682 episodes of infection. Of the 560 (56%) samples eligible for resistance testing, 269 (48.0%) were reported as wild-type, 180 (32.1%) were predicted to be resistant, 63 (11.3%) had an indeterminate resistance profile, and in 48 (8.6%) samples, N. gonorrhoeae was not detected. Ciprofloxacin was prescribed in 172 (75%) of 228 episodes in which the wild-type strain was detected. Four (2%) of those treated with ciprofloxacin had a positive test-of-cure sample by NAAT, with no reinfection risk. All four had ciprofloxacin-susceptible infection by phenotypic antimicrobial susceptibility testing. CONCLUSIONS: In routine practice in a large UK clinic, molecular ciprofloxacin resistance testing led to a significant shift in antibiotic use, reducing use of ceftriaxone. Testing can be targeted to reduce unnecessary additional testing. Longer term impact on antimicrobial resistance requires ongoing surveillance.


Subject(s)
Anti-Bacterial Agents , Ciprofloxacin , Drug Resistance, Bacterial , Gonorrhea , Microbial Sensitivity Tests , Neisseria gonorrhoeae , Humans , Ciprofloxacin/therapeutic use , Ciprofloxacin/pharmacology , Gonorrhea/drug therapy , Gonorrhea/diagnosis , Gonorrhea/microbiology , Neisseria gonorrhoeae/drug effects , Neisseria gonorrhoeae/genetics , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial/genetics , Male , Female , Adult , United Kingdom , Ceftriaxone/therapeutic use , Ceftriaxone/pharmacology , Mutation , Young Adult , Middle Aged
13.
N Z Med J ; 137(1594): 31-42, 2024 May 03.
Article in English | MEDLINE | ID: mdl-38696830

ABSTRACT

AIM: Our antimicrobial guidelines (AGs) were changed in 2021 to recommend once-daily ceftriaxone in place of three-times-daily cefuroxime as preferred cephalosporin. This analysis sought to assess the effects of this on incidence of Clostridioides difficile infection (CDI), third-generation cephalosporin-resistant Enterobacterales (3GCR-E) and resource utilisation. METHOD: Before and after analysis of 30-day CDI and 3GCR-E incidence following receipt of cefuroxime/ceftriaxone pre- and post-AG change. Total nursing time and waste production relating to cefuroxime/ceftriaxone delivery were calculated pre- and post-change. RESULTS: CDI incidence was 0.6% pre- and 1.0% post-change (adjusted odds ratio [aOR] 1.44, p=0.07) and 3GCR-E incidence 3.5% and 3.1% (aOR 0.90, p=0.33). Mean per-quarter estimated nursing administration time decreased from 2,065 to 1,163 hours (902 nurse-hour reduction) and antibiotic-related waste generation from 1,131kg to 748kg (383kg reduction). Overall days of therapy per-quarter of cefuroxime/ceftriaxone were unchanged between periods. CONCLUSION: This simplification of our AG from a three-times-daily to a once-daily antibiotic resulted in considerable savings for our hospital (roughly 1.7 full-time equivalent nurses and over a tonne of waste yearly), with no significant increases in CDI or 3GCR-E. The impact of dosing schedules on non-antibiotic-spectrum factors, such as nursing time and resource usage, is worthy of consideration when designing AGs.


Subject(s)
Anti-Bacterial Agents , Antimicrobial Stewardship , Ceftriaxone , Cefuroxime , Humans , Cefuroxime/therapeutic use , Cefuroxime/administration & dosage , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/administration & dosage , Ceftriaxone/therapeutic use , Ceftriaxone/administration & dosage , Male , Female , Clostridium Infections/drug therapy , Clostridium Infections/epidemiology , Middle Aged , Incidence , Aged , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae Infections/epidemiology , Practice Guidelines as Topic , Drug Administration Schedule
15.
J Emerg Med ; 66(5): e632-e641, 2024 May.
Article in English | MEDLINE | ID: mdl-38704306

ABSTRACT

BACKGROUND: There is a lack of evidence-based guidelines for the administration methods of ceftriaxone in emergency departments (EDs), resulting in the reliance on individual institutional protocols for decision-making. OBJECTIVE: This study was performed to compare the effects of administering ceftriaxone via intravenous push (IVP) and intravenous piggyback (IVPB) on 28-day mortality in patients with sepsis. METHODS: This was a retrospective study of patients aged 18 years or older with sepsis or septic shock who visited an ED and were treated with ceftriaxone as an initial antibiotic between March 2010 and February 2019. Patients were divided into the IVP group and the IVPB group based on the administration method. The primary outcome was 28-day mortality, and multivariable Cox proportional hazards regression analysis was performed to evaluate the relationship between antibiotic administration methods and 28-day mortality. RESULTS: During the study period, a total of 939 patients were included in the final analysis, and the overall mortality rate was 12.2%. The antibiotic administration time was significantly lower in the IVP group than in the IVPB group, and the rates of antibiotic administration within 1 h and within 3 h were higher in the IVP group than in the IVPB group (p < 0.05). However, there was no significant difference in 28-day mortality between the two groups (hazard ratio 1.07, 95% confidence interval 0.69-1.65). CONCLUSIONS: IVP administration of ceftriaxone reduced the time of antibiotic administration compared with IVPB, but there was no difference in 28-day mortality.


Subject(s)
Administration, Intravenous , Anti-Bacterial Agents , Ceftriaxone , Emergency Service, Hospital , Sepsis , Humans , Ceftriaxone/therapeutic use , Ceftriaxone/administration & dosage , Retrospective Studies , Male , Female , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/administration & dosage , Sepsis/drug therapy , Sepsis/mortality , Middle Aged , Aged , Emergency Service, Hospital/organization & administration , Proportional Hazards Models , Aged, 80 and over , Adult
16.
PLoS One ; 19(5): e0302808, 2024.
Article in English | MEDLINE | ID: mdl-38696487

ABSTRACT

BACKGROUND: One of the largest problems facing the world today is the morbidity and mortality caused by antibiotic resistance in bacterial infections. A major factor in antimicrobial resistance (AMR) is the irrational use of antibiotics. The objective of this study was to assess the prescribing pattern and cost of antibiotics in two major governmental hospitals in the West Bank of Palestine. METHODS: A retrospective cohort study was conducted on 428 inpatient prescriptions containing antibiotics from two major governmental hospitals, they were evaluated by some drug use indicators. The cost of antibiotics in these prescriptions was calculated based on the local cost. Descriptive statistics were performed using IBM-SPSS version 21. RESULTS: The mean ± SD number of drugs per prescription (NDPP) was 6.72 ± 4.37. Of these medicines, 38.9% were antibiotics. The mean ± SD number of antibiotics per prescription (NAPP) was 2.61 ± 1.54. The average ± SD cost per prescription (CPP) was 392 ± 744 USD. The average ± SD antibiotic cost per prescription (ACPP) was 276 ± 553 USD. The most commonly prescribed antibiotics were ceftriaxone (52.8%), metronidazole (24.8%), and vancomycin (21.0%). About 19% of the antibiotics were prescribed for intra-abdominal infections; followed by 16% used as prophylactics to prevent infections. Almost all antibiotics prescribed were administered intravenously (IV) 94.63%. In general, the average duration of antibiotic therapy was 7.33 ± 8.19 days. The study indicated that the number of antibiotics per prescription was statistically different between the hospitals (p = 0.022), and it was also affected by other variables like the diagnosis (p = 0.006), the duration of hospitalization (p < 0.001), and the NDPP (p < 0.001). The most commonly prescribed antibiotics and the cost of antibiotics per prescription were significantly different between the two hospitals (p < 0.001); The cost was much higher in the Palestinian Medical Complex. CONCLUSION: The practice of prescribing antibiotics in Palestine's public hospitals may be unnecessary and expensive. This has to be improved through education, adherence to recommendations, yearly immunization, and stewardship programs; intra-abdominal infections were the most commonly seen infection in inpatients and ceftriaxone was the most frequently administered antibiotic.


Subject(s)
Anti-Bacterial Agents , Practice Patterns, Physicians' , Humans , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/economics , Retrospective Studies , Female , Male , Practice Patterns, Physicians'/statistics & numerical data , Practice Patterns, Physicians'/economics , Middle East , Adult , Middle Aged , Hospitalization/economics , Drug Prescriptions/economics , Drug Prescriptions/statistics & numerical data , Ceftriaxone/therapeutic use , Ceftriaxone/economics , Drug Costs , Aged
17.
Diagn Microbiol Infect Dis ; 109(3): 116332, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38692203

ABSTRACT

We report a case of septic arthritis in a 43-year-old female patient. Despite initial treatment with ceftriaxone for Nontyphoidal Salmonella based on blood and joint fluid culture results, the shoulder joint pain worsened. Suspected systemic lupus erythematosus associated synovitis did not respond to immunosuppressive therapy including methylprednisolone, hydroxychloroquine and methotrexate. Subsequent radiograph revealed a shoulder joint abscess, leading to arthroscopic joint debridement. Ceftriaxone was administered post-operatively until analgesic efficacy was attained. This case highlights the significance of accurate diagnosis and appropriate treatment for nontyphoidal Salmonella septic arthritis.


Subject(s)
Anti-Bacterial Agents , Arthritis, Infectious , Lupus Erythematosus, Systemic , Salmonella Infections , Humans , Female , Arthritis, Infectious/microbiology , Arthritis, Infectious/drug therapy , Arthritis, Infectious/diagnosis , Adult , Lupus Erythematosus, Systemic/complications , Salmonella Infections/microbiology , Salmonella Infections/diagnosis , Salmonella Infections/drug therapy , Salmonella Infections/complications , Anti-Bacterial Agents/therapeutic use , Ceftriaxone/therapeutic use , Treatment Outcome , Debridement , Shoulder Joint/microbiology , Shoulder Joint/surgery , Salmonella/isolation & purification
18.
J Antimicrob Chemother ; 79(6): 1456-1461, 2024 Jun 03.
Article in English | MEDLINE | ID: mdl-38708907

ABSTRACT

BACKGROUND: A small proportion of Escherichia coli and Klebsiella pneumoniae demonstrate in vitro non-susceptibility to piperacillin/tazobactam but retain susceptibility to ceftriaxone. Uncertainty remains regarding how best to treat these isolates. OBJECTIVES: We sought to compare clinical outcomes between patients with piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae bloodstream infection receiving definitive therapy with ceftriaxone versus an alternative effective antibiotic. METHODS: We retrospectively identified patients with a positive blood culture for piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae between 1 January 2013 and 31 December 2022. Patients were divided into one of two definitive treatment groups: ceftriaxone or alternative effective antibiotic. Our primary outcome was a composite of 90 day all-cause mortality, hospital readmission, or recurrence of infection. We used Cox proportional hazards models to compare time with the composite outcome between groups. RESULTS: Sixty-two patients were included in our analysis. Overall, median age was 63 years (IQR 49.5-71.0), the most common source of infection was intra-abdominal (25/62; 40.3%) and the median total duration of therapy was 12.0 days (IQR 9.0-16.8). A total of 9/22 (40.9%) patients in the ceftriaxone treatment group and 18/40 (45.0%) patients in the alternative effective antibiotic group met the composite endpoint. In an adjusted time-to-event analysis, there was no difference in the composite endpoint between groups (HR 0.67, 95% CI 0.30-1.50). The adjusted Bayesian posterior probability that the HR was less than or equal to 1 (i.e. ceftriaxone is as good or better than alternative therapy) was 85%. CONCLUSIONS: These findings suggest that ceftriaxone can be used to effectively treat bloodstream infections with E. coli or K. pneumoniae that are non-susceptible to piperacillin/tazobactam but susceptible to ceftriaxone.


Subject(s)
Anti-Bacterial Agents , Bacteremia , Ceftriaxone , Escherichia coli Infections , Escherichia coli , Klebsiella Infections , Klebsiella pneumoniae , Microbial Sensitivity Tests , Piperacillin, Tazobactam Drug Combination , Humans , Ceftriaxone/therapeutic use , Ceftriaxone/pharmacology , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/isolation & purification , Middle Aged , Male , Female , Retrospective Studies , Aged , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Piperacillin, Tazobactam Drug Combination/therapeutic use , Piperacillin, Tazobactam Drug Combination/pharmacology , Escherichia coli/drug effects , Escherichia coli/isolation & purification , Bacteremia/drug therapy , Bacteremia/microbiology , Bacteremia/mortality , Klebsiella Infections/drug therapy , Klebsiella Infections/microbiology , Klebsiella Infections/mortality , Escherichia coli Infections/drug therapy , Escherichia coli Infections/microbiology , Treatment Outcome
19.
Wiad Lek ; 77(3): 608-612, 2024.
Article in English | MEDLINE | ID: mdl-38691808

ABSTRACT

A case report of Jarisch-Herxheimer (JHR) reaction on a 10th day of Leptospirosis caused by Leptospira Pomona. JHR occurs as a complication of an antibiotic treatment of various spirochetes and may lead to respiratory distress syndrome, renal failure, hepatic insufficiency, and multiple organ failure. This case represents a skin and cardio-vascular form of JHR with no lung involvement. The patient was treated with benzylpenicillin and low dexamethasone doses for 5th day of the disease with a shift to ceftriaxone and high doses of methylprednisolone. The fastest diagnosis of a sporadic zoonotic disease, early start of antibiotic therapy, and adequate doses of corticosteroids are key to the successful treatment of leptospirosis.


Subject(s)
Anti-Bacterial Agents , Leptospirosis , Humans , Male , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/adverse effects , Ceftriaxone/therapeutic use , Ceftriaxone/adverse effects , Dexamethasone/therapeutic use , Dexamethasone/adverse effects , Leptospira/isolation & purification , Leptospirosis/drug therapy , Leptospirosis/complications , Methylprednisolone/therapeutic use , Methylprednisolone/administration & dosage , Aged
20.
Sex Transm Infect ; 100(3): 173-180, 2024 Apr 18.
Article in English | MEDLINE | ID: mdl-38575313

ABSTRACT

OBJECTIVES: International travel combined with sex may contribute to dissemination of antimicrobial-resistant (AMR) Neisseria gonorrhoeae (Ng). To assess the role of travel in Ng strain susceptibility, we compared minimum inhibitory concentrations (MICs) for five antibiotics (ie, azithromycin, ceftriaxone, cefotaxime, cefixime and ciprofloxacin) in strains from clients with an exclusively Dutch sexual network and clients with an additional international sexual network. METHODS: From 2013 to 2019, we recorded recent residence of sexual partners of clients (and of their partners) with Ng at the Center for Sexual Health of Amsterdam. We categorised clients as having: (1) exclusively sexual partners residing in the Netherlands ('Dutch only') or (2) at least one partner residing outside the Netherlands. We categorised the country of residence of sexual partners by World Bank/EuroVoc regions. We analysed the difference of log-transformed MIC of Ng strains between categories using linear or hurdle regression for each antibiotic. RESULTS: We included 3367 gay and bisexual men who had sex with men (GBMSM), 516 women and 525 men who exclusively had sex with women (MSW) with Ng. Compared with GBMSM with a 'Dutch only' network, GBMSM with: (1) a Western European network had higher MICs for ceftriaxone (ß=0.19, 95% CI=0.08 to 0.29), cefotaxime (ß=0.19, 95% CI=0.08 to 0.31) and cefixime (ß=0.06, 95% CI=0.001 to 0.11); (2) a Southern European network had a higher MIC for cefixime (ß=0.10, 95% CI=0.02 to 0.17); and (3) a sub-Saharan African network had a lower MIC for ciprofloxacin (ß=-1.79, 95% CI=-2.84 to -0.74). In women and MSW, higher MICs were found for ceftriaxone in clients with a Latin American and Caribbean network (ß=0.26, 95% CI=0.02 to 0.51). CONCLUSIONS: For three cephalosporin antibiotics, we found Ng strains with slightly higher MICs in clients with partner(s) from Europe or Latin America and the Caribbean. International travel might contribute to the spread of Ng with lower susceptibility. More understanding of the emergence of AMR Ng is needed.


Subject(s)
Anti-Infective Agents , Gonorrhea , Sexual Health , Male , Female , Humans , Neisseria gonorrhoeae , Ceftriaxone/pharmacology , Ceftriaxone/therapeutic use , Cefixime/pharmacology , Gonorrhea/drug therapy , Gonorrhea/epidemiology , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Ciprofloxacin/pharmacology , Ciprofloxacin/therapeutic use , Azithromycin/pharmacology , Cefotaxime/pharmacology , Microbial Sensitivity Tests , Anti-Infective Agents/pharmacology , Drug Resistance, Bacterial
SELECTION OF CITATIONS
SEARCH DETAIL